Clinical Trials 101 in Pediatric Oncology Patients

Alicia Lenzen; Natasha Pillay Smiley

doi:10.1016/j.cpem.2018.05.001

Clinical Trials 101 in Pediatric Oncology Patients

Alicia Lenzen^*, Natasha Pillay Smiley

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

Most children with cancer are enrolled in a clinical trial, as progress is still needed for better treatments and improved prognosis. This can include phase I, II, or III trials, which vary from unknown adverse effects to well-established data. In the emergency department, it is critical to know if a patient is participating in a clinical trial and any known details or complications from the treatment. The present article reviews the fundamental foundation of clinical trial phases, as well as possible adverse effects for patients enrolled on these studies.

Original language	English (US)
Pages (from-to)	131-134
Number of pages	4
Journal	Clinical Pediatric Emergency Medicine
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.cpem.2018.05.001
State	Published - Jun 2018

Keywords

adverse effect
clinical trial
oncology
phase

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Emergency Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cpem.2018.05.001

Cite this

@article{58c13f2ab12c4f4bac7a444853799a52,

title = "Clinical Trials 101 in Pediatric Oncology Patients",

abstract = "Most children with cancer are enrolled in a clinical trial, as progress is still needed for better treatments and improved prognosis. This can include phase I, II, or III trials, which vary from unknown adverse effects to well-established data. In the emergency department, it is critical to know if a patient is participating in a clinical trial and any known details or complications from the treatment. The present article reviews the fundamental foundation of clinical trial phases, as well as possible adverse effects for patients enrolled on these studies.",

keywords = "adverse effect, clinical trial, oncology, phase",

author = "Alicia Lenzen and Smiley, {Natasha Pillay}",

note = "Funding Information: Funding: A Lenzen is supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences grant TL1TR001423 . Funding Information: Funding: A Lenzen is supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences grant TL1TR001423. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jun,

doi = "10.1016/j.cpem.2018.05.001",

language = "English (US)",

volume = "19",

pages = "131--134",

journal = "Clinical Pediatric Emergency Medicine",

issn = "1522-8401",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Clinical Trials 101 in Pediatric Oncology Patients

AU - Lenzen, Alicia

AU - Smiley, Natasha Pillay

N1 - Funding Information: Funding: A Lenzen is supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences grant TL1TR001423 . Funding Information: Funding: A Lenzen is supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences grant TL1TR001423. Publisher Copyright: © 2018 Elsevier Inc.

PY - 2018/6

Y1 - 2018/6

N2 - Most children with cancer are enrolled in a clinical trial, as progress is still needed for better treatments and improved prognosis. This can include phase I, II, or III trials, which vary from unknown adverse effects to well-established data. In the emergency department, it is critical to know if a patient is participating in a clinical trial and any known details or complications from the treatment. The present article reviews the fundamental foundation of clinical trial phases, as well as possible adverse effects for patients enrolled on these studies.

AB - Most children with cancer are enrolled in a clinical trial, as progress is still needed for better treatments and improved prognosis. This can include phase I, II, or III trials, which vary from unknown adverse effects to well-established data. In the emergency department, it is critical to know if a patient is participating in a clinical trial and any known details or complications from the treatment. The present article reviews the fundamental foundation of clinical trial phases, as well as possible adverse effects for patients enrolled on these studies.

KW - adverse effect

KW - clinical trial

KW - oncology

KW - phase

UR - http://www.scopus.com/inward/record.url?scp=85047738877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047738877&partnerID=8YFLogxK

U2 - 10.1016/j.cpem.2018.05.001

DO - 10.1016/j.cpem.2018.05.001

M3 - Article

AN - SCOPUS:85047738877

SN - 1522-8401

VL - 19

SP - 131

EP - 134

JO - Clinical Pediatric Emergency Medicine

JF - Clinical Pediatric Emergency Medicine

IS - 2

ER -

Clinical Trials 101 in Pediatric Oncology Patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this